NASDAQ$ALXO
ALX Oncology Holdings Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
ALX Oncology reported positive interim Phase 2 ASPEN-06 clinical trial results for evorpacept for the treatment of advanced HER2-positive gastric/gastroesophageal junction (GEJ) cancer, completed a public offering generating gross proceeds of approximately $63.2 million, and realigned its leadership team.
- Reported positive interim Phase 2 ASPEN-06 clinical trial results for evorpacept for the treatment of advanced HER2-positive gastric/gastroesophageal junction (“GEJ”) cancer.
- Completed public offering generating gross proceeds of approximately $63.2 million.
- Realigned leadership team to match platform asset evorpacept’s maturing portfolio of programs and refined long-term development strategy.
- Advanced pipeline of nine programs evaluating evorpacept in combination with anti-cancer antibodies, antibody-drug conjugates (“ADCs”), and PD-1/PD-L1 immune checkpoint inhibitors.
Headline financials
Revenue & EPS history
ALX Oncology · Revenue · Quarterly
$0
Forward guidance
ALX Oncology believes its cash, cash equivalents, and investments along with the ability to draw down an additional $40 million of its term loan and the net proceeds from its recent public offering are sufficient to fund planned operations into early 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+1.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.7%
Avg return
30 days after
59%
13 / 22 earnings
Positive
+26.0%
Q4 2024
Best reaction
-21.9%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -10.2% | -6.8% | -13.2% | |
| Q3 2025 | +15.5% | +8.5% | +20.3% | |
| Q2 2025 | +7.4% | +57.9% | +72.4% | |
| Q1 2025 | -8.2% | -0.2% | +25.9% | |
| Q4 2024 | +26.0% | -6.4% | -50.4% | |
| Q3 2024 | -5.2% | -12.4% | +5.9% | |
| Q1 2024 | -2.4% | -8.7% | -45.8% | |
| Q4 2023 | +3.0% | -16.2% | -17.2% | |
| Q3 2023 | +13.2% | +21.8% | +70.5% | |
| Q2 2023 | +1.4% | -2.6% | -1.4% | |
| Q1 2023 | +0.6% | -7.0% | +23.3% | |
| Q4 2022 | -13.6% | -15.9% | -28.7% | |
| Q3 2022 | -1.8% | +1.1% | -14.2% | |
| Q2 2022 | +2.6% | +26.6% | +5.6% | |
| Q1 2022 | -6.8% | -8.1% | -24.1% | |
| Q4 2021 | +7.7% | -1.3% | +2.7% | |
| Q3 2021 | +8.8% | +6.3% | -26.4% | |
| Q2 2021 | +0.6% | +2.1% | +16.6% | |
| Q1 2021 | -1.1% | -1.6% | +7.3% | |
| Q4 2020 | -21.9% | -19.4% | -24.8% | |
| Q3 2020 | +4.2% | +34.6% | +65.1% | |
| Q2 2020 | +2.0% | -3.8% | -10.0% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro